. Author manuscript; available in PMC: 2023 Jan 1.

Published in final edited form as: J Minim Invasive Gynecol. 2021 Jul 13;29(1):119–127. doi: 10.1016/j.jmig.2021.07.004

TABLE 3.

Patient outcomes by timing of leiomyosarcoma diagnosis (N=79)

Patient Outcomes	Diagnosed Preoperatively (N=46)	Diagnosed Postoperatively (N=33)	P Value
Type of hysterectomy			.002
Total/radical hysterectomy	46 (100.0%)	26 (78.8%)
Supracervical hysterectomy	0 (0%)	7 (21.2%)
Length of stay (days), mean±SD, median (interquartile range)	4.4±6.6, 3 (2–5)	4.2±2.6, 4 (2–5)	.32
Blood transfusion			.01
Yes	8 (17.4%)	14 (42.4%)
No	38 (82.6%)	19 (57.6%)
Reoperation (within 4 months after hysterectomy)			.07
Yes	0 (0%)	3 (9.1%)
No	46 (100.0%)	30 (90.9%)
Re-admission (within 4 months after hysterectomy)			.78
Yes	14 (30.4%)	11 (33.3%)
No	32 (69.6%)	22 (66.7%)
Radiation therapy^a			.75
Yes	7 (15.9%)	4 (12.1%)
No	37 (84.1%)	29 (87.9%)
Chemotherapy^b			.87
Yes	21 (45.7%)	14 (43.8%)
No	25 (54.3%)	18 (56.3%)
Mortality risk
All-cause mortality
Unadjusted, hazard ratio (95% CI)	Reference	1.15 (0.61–2.17)	.66
Adjusted,^c hazard ratio (95% CI)	Reference	0.87 (0.41–1.85)	.72
Disease-specific mortality
Unadjusted, hazard ratio (95% CI)	Reference	1.16 (0.54–2.52)	.70
Adjusted,^c hazard ratio (95% CI)	Reference	0.65 (0.24–1.75)	.39

CI = confidence interval; SD = standard deviation.

^a.

N=2 patients had missing data.

^b.

N=1 patient had missing data.

^c.

After adjustment for patient age, race/ethnicity, cancer stage, grade, tumor size, and number of comorbidities.